Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01928368 | A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma. | PHASE1 | COMPLETED | 70 | — | — | Aug 1, 2013 | Mar 1, 2016 | Dec 14, 2016 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| Experimental Arm | ACTIVE_COMPARATOR | - |
| Placebo Arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AMG 282 | DRUG | Single dose either subcutaneously or intravenously on day 1. |
| AMG 282 Matching Placebo | DRUG | Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1. |
Inclusion Criteria (All subjects) * Is a current non-smoker, has not used any nicotine or tobacco containing products (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, pipes, or nicotine patches) within the last 6 months, and cumulative smoking history is ≤10 pack years. * ...